Skip to main content

The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study

The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study

Source :

https://link.springer.com/article/10.1007/s00415-021-10523-8

Objective To evaluate the frequency and headache-related impact response to monoclonal antibodies against calcitonin gene-related peptide (CGRP) in a clinical sample of refractory migraine patients. Methods We included migraine patients with ≥ 8 headache days/month that had failed at least three preventive medications. Demographic, medical and migraine history were collected.

  • 2 weeks 3 days
    This validates previous studies showing that cGRP inhibitors work well in resistant patients.
  • from Doctor Unite 2 weeks 4 days
    This study shows proof that anti-CGRPs are effective at decreasing migraine days.
  • 2 weeks 5 days
    This observational study supports prior RTC studies of CGRP mab showing significant reduction in headache and migraine days with this treatment. Often it is confusing to see that the migraine days are reduced more than headache days but I think this represents the fact that the headaches that continue to occur are milder and therefore not termed migraines.